title: Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia.
abstract: OBJECTIVE
  This study investigated the efficacy, safety, tolerability, and pharmacokinetics of a novel cholesterol absorption inhibitor, FM-VP4, comprising disodium ascorbyl sitostanol phosphate (DASP) and disodium ascorbyl campestanol phosphate (DACP).
  
  
  METHODS
  In phase 1, 30 men received a single dose of 100, 200, 400, 800, 1,600, or 2,000 mg FM-VP4 or placebo. In phase 2, 100 men were treated with 100, 200, 400, or 800 mg/day of FM-VP4 or placebo for 4 weeks.
  
  
  RESULTS
  The drug was well tolerated at each single or multiple dose level. After 4 weeks of treatment, low-density lipoprotein cholesterol (LDL-C) levels changed by 2.7% in the placebo group and by 2.9%, -4.2%, and -4.6% in the 100, 200, and 800 mg/day groups, respectively, which was not statistically significant. However, 400 mg/day of FM-VP4 significantly decreased LDL-C by 6.5% (p=0.02). Phase 1 showed that DACP and DASP were absorbed into plasma with a median t(max) of 12 h for both components, and clearance was slow with a mean t(1/2lambda) of 57 h. During 4 weeks of treatment, steady state was reached by approximately 8 days.
  
  
  CONCLUSIONS
  This study demonstrated that up to 800 mg/day of FM-VP4 is safe and well tolerated for at least 4 weeks. Furthermore, the higher doses significantly reduced LDL-C by 7% compared with baseline or by 10% compared with placebo, with the maximum effect reached at 400 mg/day.
authors.affiliation: Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9 F4-159.2, 1105 AZ, Amsterdam, The Netherlands. m.n.vissers@amc.uva.nl
authors.forename: Maud N
authors.initials: MN
authors.lastname: Vissers
authors.forename: Mieke D
authors.initials: MD
authors.lastname: Trip
authors.forename: P Haydn
authors.initials: PH
authors.lastname: Pritchard
authors.forename: Patrick
authors.initials: P
authors.lastname: Tam
authors.forename: Tatjana
authors.initials: T
authors.lastname: Lukic
authors.forename: Monique G
authors.initials: MG
authors.lastname: de Sain-van der Velden
authors.forename: Martina
authors.initials: M
authors.lastname: de Barse
authors.forename: John J P
authors.initials: JJ
authors.lastname: Kastelein
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019540:Area Under Curve; D001794:Blood Pressure; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D050171:Dyslipidemias / Q000188:drug therapy*; D004562:Electrocardiography; D008401:Gas Chromatography-Mass Spectrometry; D006207:Half-Life; D006339:Heart Rate; D006801:Humans; D008297:Male; D008875:Middle Aged; D010840:Phytosterols / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010919:Placebos
chemical_list: D000924:Anticholesteremic Agents; C445524:FM-VP4 compound; D010840:Phytosterols; D010919:Placebos